Evaluation the efficacy and safety of Zanubrutinib + R-CHOP/R-DHAP for the treatment mantle cell lymphoma.
Histologically confirmed diagnosis of MCL according to WHO classification;
Previously untreated MCL.
Age ≥ 18 and ≤ 70 years old.
ECOG, 0~2.
Known CNS involvement of MCL, Leukemic non-lymphonodular mantle cell lymphoma was excluded.
Major surgery within 4 weeks of screening
Concomitant or previous malignancies within the last 2 years other than basal cell skin cancer or in situ uterine cervix cancer
Clinically significant cardiovascular disease such as uncontrolled arrhythmias and hypertension , congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below 50%（AHA，2016）